Armaan F. Akbar

Armaan F. Akbar


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJen-Zen Chuang
Jen-Zen Chuang
NAN YangNAN Yang
NAN Yang
NNNobuyuki Nakajima
Nobuyuki Nakajima
WOWataru Otsu
Wataru Otsu
CFCheng Fu
Cheng Fu
CSChing-Hwa Sung
Ching-Hwa Sung
Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. Dry AMD has unclear etiology and no treatment. Lipid-rich drusen are the hallmark of dry AMD. An AMD mouse model and insights into drusenogenesis are keys to better understanding of this disease. Chloride intracellular channel 4 (CLIC4) is a pleomorphic protein regulating diverse biological functions. Here we show that retinal pigment epithelium (RPE)-specific Clic4 knockout mice exhibit a full spectrum of functional and pathological hallmarks of dry AMD. Multidisciplinary longitudinal studies of disease progression in these mice support a mechanistic model that links RPE cell-autonomous aberrant lipid metabolism and transport to drusen formation.

22 April 2023 in Lung
Verified
Journal Article
Closed access
PDF file
AAArmaan F. Akbar
Armaan F. Akbar
BSBenjamin L. Shou
Benjamin L. Shou
CFCheng-Yuan Feng
Cheng-Yuan Feng
DZDavid X. Zhao
David X. Zhao
BKBo Soo Kim
Bo Soo Kim
PBPatricia Brown
Patricia Brown

31 October 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AZAlice L. Zhou
Alice L. Zhou
MJMaria R. Jennings
Maria R. Jennings
AAArmaan F. Akbar
Armaan F. Akbar
JRJessica Moore Ruck
Jessica Moore Ruck
AOAtharv Oak
Atharv Oak
EBErrol L. Bush
Errol L. Bush


17 January 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AZAlice L. Zhou
Alice L. Zhou
AAArmaan F. Akbar
Armaan F. Akbar
ARAlexandra A. Rizaldi
Alexandra A. Rizaldi
JRJessica Moore Ruck
Jessica Moore Ruck
ELEmily L. Larson
Emily L. Larson
AKAhmet Kilic
Ahmet Kilic

27 August 2024 in Neurology
Verified
Journal Article
Closed access
JHJaeho Hwang
Jaeho Hwang
AAArmaan F. Akbar
Armaan F. Akbar
LPLavienraj Premraj
Lavienraj Premraj
EREva K. Ritzl
Eva K. Ritzl
Sung-Min ChoSung-Min Cho
Sung-Min Cho
Extracorporeal membrane oxygenation (ECMO) provides lifesaving support to patients with cardiopulmonary failure. Although seizures increase mortality risks among critically ill patients broadly, studies specific to adult ECMO patients have largely been limited to single-center studies. Thus, we aimed to perform a systematic review and meta-analyses of seizure prevalence, mortality, and their associations in adult ECMO patients. PubMed, EMBASE, Cochrane trial registry, Web of Science, and SCOPUS were searched on August 5, 2023. Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we included studies of adults undergoing venovenous ECMO (VV-ECMO), venoarterial ECMO (VA-ECMO), or extracorporeal cardiopulmonary resuscitation (ECPR) that reported seizures during ECMO. The extracted data included study characteristics, patient demographics, ECMO support, EEG monitoring, and seizures, organized by ECMO types. Forest plot and meta-regression analyses were performed. Bias assessment was performed with the Egger test and Newcastle-Ottawa Scale. Twenty-three studies (n = 40,420, mean age = 51.8 years, male = 62%) were included. Data were extracted by ECMO type as follows: VV-ECMO (n = 16,633), non-ECPR VA-ECMO (n = 11,082), ECPR (n = 3,369), combination of VA-ECMO and ECPR (n = 240), and combination of all types (n = 9,096). The pooled seizure prevalence for all ECMO types was 3.0%, not significantly different across ECMO types (VV-ECMO = 2.0% [95% CI 0.8-4.5]; VA-ECMO = 3.5% [95% CI 1.7-7.0]; ECPR = 4.9% [95% CI 1.3-17.2]). The pooled mortality was lower for VV-ECMO (46.2% [95% CI 39.3-53.2]) than VA-ECMO (63.4% [95% CI 56.6-69.6]) and ECPR (61.5% [95% CI 57.3-65.6]). Specifically, for VV-ECMO, the pooled mortality of patients with and without seizures was 55.1% and 36.7%, respectively (relative risk = 1.5 [95% CI 1.3-1.7]). Similarly, for VA-ECMO, the pooled mortality of patients with and without seizures was 74.4% and 56.1%, respectively (relative risk = 1.3 [95% CI 1.2-1.5]). Meta-regression analyses demonstrated that seizure prevalence was not associated with prior neurologic comorbidities, adjusted for ECMO type and study year. Seizures are infrequent during ECMO support. However, they were associated with increased mortality when present. Multi-institutional, larger-scale studies using standardized EEG monitoring are necessary to further understand the risk factors of specific classes of seizures for individual ECMO types, and their effects on mortality. Limitations of our study include missing data for details on seizure types, sedating/antiseizure medications used during ECMO, other ECMO-related complications, and EEG recording protocols.